Axiom/Protocols
+ New intake
SS-31

Evidence — SS-31

peptide · asset evidence level: clinical

Evidence quality breakdown (linked documents)

expert_opinion: 11preclinical: 1

Linked source documents (12)

Provider dosing references (Stage 9, source-attributed)

Investigational; commonly studied at 40 mg SC daily - provider-directed Practitioner Peptide Dosing Reference (commonly published ranges)
40 mg subcutaneous daily (Phase 3 dose); or 5-10 mg daily (research community range) Peptide Protocol Wiki (peptideprotocolwiki.com)
Standard: 40 mg · Low: 20 mg Peptide Dosing Protocols (peptidedosingprotocols.com)

Dosing claims (147) · Safety claims (30)

Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.